ストックスクリーナーアプリを入手
6.72
1.05%
0.07
前日終値:
$6.65
開ける：
$6.73
24時間の取引高:
77,223
Relative Volume:
0.47
時価総額：
$233.27M
収益：
$44.64M
当期純損益:
$-10.10M
株価収益率:
-19.53
EPS:
-0.344
ネットキャッシュフロー:
$-14.45M
1週間 パフォーマンス:
+0.30%
1か月 パフォーマンス:
+4.67%
6か月 パフォーマンス:
-18.55%
1年 パフォーマンス:
+7.01%
1日の値動き範囲:
$6.65
$6.935
1週間の範囲:
$6.13
$6.935
52週間の値動き範囲:
$5.65
$9.92
Fennec Pharmaceuticals Inc Stock (FENC) Company Profile
名前
Fennec Pharmaceuticals Inc
セクター
電話
(919) 636-4530
住所
PO BOX 13628, RESEARCH TRIANGLE PARK, NC
Compare FENC vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
FENC
Fennec Pharmaceuticals Inc
|
6.72 | 230.84M | 44.64M | -10.10M | -14.45M | -0.344 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Fennec Pharmaceuticals Inc Stock (FENC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-12 | 開始されました | B. Riley Securities | Buy |
| 2026-01-09 | 開始されました | Piper Sandler | Overweight |
| 2022-11-22 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2022-09-07 | 開始されました | CapitalOne | Overweight |
| 2022-08-08 | 再開されました | Craig Hallum | Buy |
| 2020-06-05 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-10-11 | 開始されました | Goldman | Buy |
すべてを表示
Fennec Pharmaceuticals Inc (FENC) 最新ニュース
FENC (Fennec Pharmaceuticals) posts far wider than expected Q4 2025 loss even as shares tick higher.Expert Verified Trades - Newser
Book value per share of Fennec Pharmaceuticals Inc. – TSX:FRX - TradingView
Insider Selling: Adherex Technologies (NASDAQ:FENC) Director Sells 10,781 Shares of Stock - MarketBeat
Director at Fennec (NASDAQ: FENC) sells shares after tax-related option exercise - Stock Titan
FENC (NASDAQ: FENC) insider files Form 144 to sell 10,781 shares - Stock Titan
Fennec (NASDAQ: FENC) CCO acquires 168 newly released shares - Stock Titan
Fennec Pharmaceuticals (NASDAQ: FENC) CSO gains 155 vested shares - Stock Titan
Fennec (FENC) CEO acquires 1,159 shares as restrictions lift - Stock Titan
Fennec Pharmaceuticals (FENC) CFO gains 1,703 additional shares - Stock Titan
Restricted share vesting adds 168 shares for Fennec (FENC) CMO - Stock Titan
FENC Stock Price, Quote & Chart | FENNEC PHARMACEUTICALS INC (NASDAQ:FENC) - ChartMill
Director to retire as Fennec Pharmaceuticals (FENC) Board shrinks to five seats - Stock Titan
1.98M shares disclosed by Fennec holders (NASDAQ: FENC) in Schedule 13G - Stock Titan
Large equity incentive proposals at Fennec Pharmaceuticals (NASDAQ: FENC) 2026 meeting - Stock Titan
(FENC) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Adherex Technologies Inc. (NASDAQ:FENC) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
FENC Fennec Pharmaceuticals Inc. reports wider than expected Q4 2025 loss, as shares rise nearly 8 percent in today’s trading.FCF Yield - Cổng thông tin điện tử Tỉnh Sơn La
Fennec Showcases New PEDMARK Data at 2026 ASCO - TipRanks
Fennec Pharmaceuticals (FENC) to feature four PEDMARK ototoxicity studies at ASCO 2026 - Stock Titan
Fennec Pharmaceuticals advances PEDMARK as four abstracts accepted for ASCO scientific program - Traders Union
Fennec Pharmaceuticals : Announces Investigator-Sponsored Study to Be Conducted by University of Arizona Cancer Center - marketscreener.com
Fennec Announces Acceptance of Abstracts at the 2026 ASCO Annual Meeting - marketscreener.com
Fennec Pharmaceuticals Announces Acceptance of Abstracts at the 2026 ASCO Annual Meeting - The Manila Times
Four ASCO studies spotlight hearing-loss risk tied to cisplatin - Stock Titan
Fennec Pharmaceuticals (FENC) Stock One Cancels Other (Weakens) 2026-04-20Most Watched Stocks - Xã Vĩnh Công
(FRX) Strategic Equity Report (FRX:CA) - Stock Traders Daily
Fennec Pharmaceuticals (TSE:FRX) Stock Price Passes Below Fifty Day Moving AverageHere's What Happened - MarketBeat
Fennec Pharmaceuticals (FENC) Receives a Buy from Wedbush - The Globe and Mail
Adherex Technologies (NASDAQ:FENC) Given "Outperform" Rating at Wedbush - MarketBeat
(FENC) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Fennec Pharmaceuticals (FENC) Stock Dividend Capture (Ticks Up) 2026-04-15Senior Analyst Forecasts - Cổng thông tin điện tử tỉnh Lào Cai
(FRX) Trading Report (FRX:CA) - Stock Traders Daily
Treasury Yields: Can Fennec Pharmaceuticals Inc stock outperform in a bear market2026 Reactions & Verified Entry Point Detection - baoquankhu1.vn
US Market Recap: What is the long term forecast for Fennec Pharmaceuticals Inc stock2026 Key Lessons & Long-Term Growth Portfolio Plans - baoquankhu1.vn
Stock Recap: Can Fennec Pharmaceuticals Inc expand its profit marginsGap Up & Low Risk High Reward Ideas - baoquankhu1.vn
Fennec Pharmaceuticals (TSE:FRX) Shares Cross Below Fifty Day Moving AverageWhat's Next? - MarketBeat
FRX.CA Forecast, Price Target & Analyst Ratings | FENNEC PHARMACEUTICALS INC (TSX:FRX) - ChartMill
Aug Spikes: Why is Fennec Pharmaceuticals Inc stock going down2026 Macro Impact & Fast Exit Strategy with Risk Control - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Denali Therapeutics (DNLI) and Fennec Pharmaceuticals (FENC) - The Globe and Mail
H.C. Wainwright reiterates Fennec Pharmaceuticals stock rating on expanded study - Investing.com India
H.C. Wainwright reiterates Fennec Pharmaceuticals stock rating on expanded study By Investing.com - Investing.com South Africa
Fennec Pharmaceuticals Announces New Investigator-Sponsored Study of PEDMARK® for Preventing Cisplatin-Induced Hearing Loss in AYA and Adult Cancer Patients - Minichart
Fennec Pharmaceuticals Inc. (FENC) stock price, news, quote and history - Yahoo Finance UK
Fennec Pharmaceuticals: University of Arizona launches PEDMARK study in AYA and adult cisplatin patients - TradingView
Fennec (FENC) backs new University of Arizona study on PEDMARK use in cisplatin-treated patients - Stock Titan
Fennec Pharmaceuticals Inc. Announces Investigator-Sponsored Study of PEDMARK in AYA and Adult Patients With Solid Tumors Receiving Cisplatin - marketscreener.com
Fennec Pharmaceuticals urges focus on community and science to shape a healthier world - Traders Union
Fennec Pharmaceuticals: University Of Arizona Cancer Center Investigator-Sponsored Study Advances PEDMARK In AYA And Adult Cancer Patients - Pulse 2.0
FENC Technical Analysis & Stock Price Forecast - Intellectia AI
Fennec Backs New PEDMARK Study Expanding Cisplatin Ototoxicity Research to Adult Cancers - TipRanks
Fennec Pharmaceuticals Announces Investigator-Sponsored Study to Be Conducted by University of Arizona Cancer Center - Bitget
Fennec Pharmaceuticals Inc (FENC) 財務データ
収益
当期純利益
現金流量
EPS
0.14%
0.48%
大文字化:
|
ボリューム (24 時間):